Biotech | March 29, 2022
USFDA clears IND application for an intranasal RSV vaccine
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Data to establish the safety profile and human dose of vaccine candidate
Data published in the prestigious journal ACS Central Science of the American Chemical Society
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Subscribe To Our Newsletter & Stay Updated
